MannKind Corp, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes diseases in the United States. Its approved product is Afrezza, a rapid-acting, inhaled insulin used to control high blood sugar in adults with type 1 and type 2 diabetes. The company was founded in 1991 and is headquartered in Westlake Village, California.
(Summary) (Company) (Chart)
9 October 2017 Price $5.33 1yr Target $7.00 Analysts 1 Dividend $0.00 Payout Ratio 0.00% 1yr Cap Gain 31.33% Yield 0.00% 1yr Tot Return 31.33% P/E 3.95 PEG 0.15 Beta 2.91 | EPS (ttm) $1.35 EPS next yr $-0.84 Forward P/E --- EPS next 5yr 26.80% 1yr Price Support --- Market Cap $398.26 Mil Revenues $179.90 Mil Earnings $128.80 Mil Profit Margin 71.59% Quick Ratio 0.60 Current Ratio 0.60 Debt/Equity --- | 1yr RevGR --- 3yr RevGR --- 5yr RevGR --- 1yr EarnGR --- 3yr EarnGR --- 5yr EarnGR --- 1yr DivGR --- 3yr DivGR --- 5yr DivGR --- ROA 140.10% ROE -62.10% |